Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AP-SA02

Other · developed by Armata Pharmaceuticals

Phase 1/2 Most advanced trial (none active)

ARMP Developer

1 Registered trials

What is AP-SA02?

AP-SA02 is a bacteriophage administered by intravenous bolus infusion. It is studied in bacteremia caused by Staphylococcus aureus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Infectious disease
Developer: Armata Pharmaceuticals, Inc. (ARMP)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05184764	Phase 1/2	Bacteremia	Completed	ARMP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

BacteremiaBacteremia Due to Staphylococcus AureusBacteremia StaphStaphylococcus AureusStaphylococcus Aureus Bacteremia

More from Armata Pharmaceuticals

AB-PA01 N/A AB-SA01 Phase 1 AP-PA02 Phase 2 C16G2 Phase 2 C16G2 Rinse Phase 2 C16G2 Strip Phase 2

Sources

ClinicalTrials.gov NCT05184764

Updated Oct 11, 2026. Something wrong or missing? Report it on the ARMP page.

Follow ARMP, the company behind AP-SA02

See ARMP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARMP catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z